Clinical Trials
12 trialsNCT06203600 2026-05-26
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT06161025 2026-05-22
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
NCT06712316 2026-05-22
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
BioNTech SE
Phase 2/3 Recruiting
NCT07063745 2026-05-18
MountainTAP-29
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT05255653 2026-05-15
RAINBO
Leiden University Medical Center
Phase 2/3 Recruiting
NCT06926868 2026-04-30
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07131319 2026-02-02
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Second Affiliated Hospital of Nanchang University
Phase 2/3 Recruiting
NCT06123884 2025-02-10
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS â¥1) Cervical Cancer
Bio-Thera Solutions
Phase 2/3 Recruiting
NCT06221748 2024-04-03
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
RemeGen Co., Ltd.
Phase 2/3 Recruiting
NCT05427383 2023-12-19
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
Shanghai JMT-Bio Inc.
Phase 2/3 Recruiting
NCT03150576 2022-11-14
PARTNER
Cambridge University Hospitals NHS Foundation Trust
Phase 2/3 Recruiting
NCT04576143 2021-08-12
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2/3 Recruiting